2024-01-31 11:58:09 ET
Novo Nordisk A/S (NVO)
Q4 2023 Earnings Conference Call
January 31, 2024 07:00 AM ET
Company Participants
Daniel Bohsen - Head of Investor Relations
Lars Fruergaard Jorgensen - President and Chief Executive Officer
Camilla Sylvest - Executive Vice President and Head of Commercial Strategy and Corporate Affairs
Doug Langa - Executive Vice President and Head of North America Operations
Martin Holst Lange - Executive Vice President and Head of Development
Karsten Munk Knudsen - Chief Financial Officer
Conference Call Participants
Richard Vosser - JPMorgan
Harry Sephton - UBS
Emily Field - Barclays
Michael Nedelcovych - TD Cowen
Peter Verdult - Citigroup
Louise Chen - Cantor Fitzgerald
Sachin Jain - Bank of America Merrill Lync
Martin Parkhoi - SEB
Seamus Fernandez - Guggenheim Securities
Simon Baker - Redburn Atlantic
Mark Purcell - Morgan Stanley
Richard Parkes - BNP Paribas Exxon
Michael Novod - Nordea Markets
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q4 2023 Novo Nordisk Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Daniel Bohsen, CVP and Investor Relations. Please go ahead.
Daniel Bohsen
Welcome to this Novo Nordisk Earnings Call for the full-year of 2023 and outlook for 2024. My name is Daniel Muusmann Bohsen, and I'm the Head of Investor Relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Lars Fruergaard Jørgensen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally, Chief Financial Officer, Karsten Munk Knudsen. All speakers will be available for the Q&A session.
Today's announcement and the slides for this call are available on our website, novonordisk.com. Please note that the call is being webcast live and the recording will be made available on our website as well. The call is scheduled to last one hour. Please turn to the next slide. The presentation is structured as outlined on Slide 2. Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified.
Please turn to Slide 3. We need to advise you that this call will contain forward-looking statements. These are subject to risks and uncertainty that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company announcement for the full-year 2023 and the slides prepared for this presentation. With this, over to you, Lars on update on our strategic aspirations....
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript